Loading patent…
AssigneesMelbourne Health, Austin Health, Southern Health, Alfred Health, St. Vincent's Hospital Melbourne
InventorsAngeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Lilly Ka Wai Yuen, Joseph John Sasadeusz
Estimating the term…
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
A method for determining whether an HBV strain exhibits reduced sensitivity to Adefovir said method comprising isolating DNA or corresponding mRNA from the HBV strain and screening for the presence of a mutation in the nucleotide sequence encoding the HBV DNA polymerase resulting in a substitution in the amino acid sequence of the HBV DNA polymerase selected from the group consisting of rtQ215S and rtV253G, wherein the foregoing amino acid positions are numbered in reference to the M of the YMDD motif of the HBV DNA polymerase being position 204 and wherein the presence of said mutation is indicative of an HBV variant that exhibits a decreased sensitivity to Adefovir.
Dependencies are inferred from the claim text.